Lbp Am Sa Increases Position in Boston Scientific Corporation $BSX

Lbp Am Sa raised its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 38.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 400,859 shares of the medical equipment provider’s stock after acquiring an additional 110,583 shares during the quarter. Lbp Am Sa’s holdings in Boston Scientific were worth $39,136,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in BSX. Vanguard Group Inc. raised its stake in Boston Scientific by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock valued at $14,729,575,000 after purchasing an additional 2,545,381 shares during the period. State Street Corp grew its holdings in Boston Scientific by 1.1% during the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after buying an additional 713,379 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Boston Scientific by 2.0% during the second quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock valued at $3,466,320,000 after buying an additional 622,602 shares during the last quarter. Norges Bank purchased a new position in shares of Boston Scientific in the second quarter worth $2,089,937,000. Finally, Invesco Ltd. lifted its holdings in shares of Boston Scientific by 1.4% in the second quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider’s stock worth $1,810,022,000 after buying an additional 226,578 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 1.4%

NYSE BSX opened at $92.56 on Monday. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. Boston Scientific Corporation has a 52 week low of $85.98 and a 52 week high of $109.50. The firm has a market capitalization of $137.22 billion, a price-to-earnings ratio of 49.50, a PEG ratio of 1.68 and a beta of 0.67. The company has a fifty day moving average of $95.70 and a two-hundred day moving average of $99.83.

Analysts Set New Price Targets

A number of brokerages have issued reports on BSX. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Wells Fargo & Company lifted their target price on Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. The Goldman Sachs Group restated a “buy” rating and set a $112.00 price target on shares of Boston Scientific in a report on Friday, January 9th. Robert W. Baird boosted their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Finally, Erste Group Bank lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $123.89.

Insider Buying and Selling at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. This represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the sale, the director directly owned 24,134 shares of the company’s stock, valued at $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 83,105 shares of company stock worth $8,295,161 over the last 90 days. Company insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.